There are established CSF biomarkers for brain disorders, such as tau, phosphorylated tau, and β-amyloid proteins for Alzheimer’s disease (AD), which can be used to diagnose AD with a high (~90%) sensitivity and specificity10. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.